Savara (NASDAQ:SVRA) Announces Earnings Results

Savara (NASDAQ:SVRA) posted its earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports.

Savara Stock Performance

SVRA traded down $0.30 during trading hours on Thursday, hitting $5.40. The company’s stock had a trading volume of 488,360 shares, compared to its average volume of 1,611,780. The company has a 50-day simple moving average of $5.65 and a 200 day simple moving average of $5.49. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.11 billion, a PE ratio of -9.30 and a beta of 0.29. Savara has a fifty-two week low of $2.68 and a fifty-two week high of $7.01.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Finally, Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. bought a new stake in shares of Savara during the second quarter valued at about $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new position in Savara during the 2nd quarter valued at about $33,000. Russell Investments Group Ltd. raised its position in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Savara during the 3rd quarter worth about $44,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.